A Study of the Efficacy and Safety of Enclitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-008)

Clinical trial NCT05261126 · COMPLETED

Trial details

NCT number: NCT05261126
Sponsor: Merck Sharp & Dohme LLC
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Hypercholesterolemia Familial Hypercholesterolemia

Start date: 2022-03-10
Primary completion: 2022-11-28
Enrollment: 381

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.